FDA Clears Siemens Healthineers BRAHMS PCT Assay

Aug 03, 2018

|

NEW YORK (360Dx) – Siemens Healthineers has received US Food and Drug Administration clearance for the Atellica IM BRAHMS PCT Assay for sepsis assessment, assigning mortality risk, and antibiotic therapy decision-making in the emergency department and intensive care unit.

Michael Reitermann, president of the diagnostics segment, Siemens Healthineers, announced the clearance during a presentation this week at the 70th American Association for Clinical Chemistry Scientific Meeting & Clinical Lab Expo in Chicago.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

Use of the LumiraDx SARS-CoV-2 Antigen Test in Pediatric Practice

Performance Evaluation of the LumiraDx SARS-CoV-2 Antigen Test to Aid Diagnosis of Acute COVID-19 at the Point of Care

An Evaluation of the Detection of SARS-CoV-2 Antigen in a Cohort of Symptomatic and Asymptomatic Patients: Report from the Evaluation of SKUP

Agena Bioscience’s SARS-CoV-2 Tests: Providing Resilience Against the Emergence of New Variants

Mar

18

Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Viruses mutate as they strive to thrive in response to selective pressures.

Mar

29

Featured Webinar

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Apr

06

Featured Webinar

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.

Apr

16

Featured Webinar

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Menu

FDA Clears Siemens Healthineers BRAHMS PCT Assay

To read the full story....

Breaking News

Germany Approves COVID-19 Rapid Antigen Tests for Home Use

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

DermTech Q4 Revenues Up 31 Percent

In Brief This Week: Abbott Laboratories, LexaGene, Caris Life Sciences, SQI Diagnostics, and More

PerkinElmer to Offer $800M in Senior Notes

Featured White Papers

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Reducing COVID-19 Infections Rates at a University Campus with Mass Screening

The Post-Vaccine COVID Testing Landscape: A Virtual Roundtable Discussion

What's Popular?

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

OraSure Technologies Updates Plan for SARS-CoV-2 Antigen Self-Test

Luminex Obtains FDA Emergency Use Authorization for Expanded Respiratory Panel With SARS-CoV-2

Germany Approves COVID-19 Rapid Antigen Tests for Home Use

Oxford Immunotec Nabs CE Mark for COVID-19 T-Cell Response Test

Sponsorships